Taking on gamma delta T cells, bluebird pays $16M for TC BioPharm's tumor invading tech platform
Gene therapy pioneer bluebird bio is teaming up with Scotland’s TC BioPharm to get its hands on an experimental program involving an emerging immunotherapy platform: CAR-engineered gamma delta T cells.
As part of the deal, bluebird $BLUE is paying TC BioPharm (TCB) a $16 million upfront payment, with undisclosed milestones and royalties down the road. TCB will be responsible for developing targets through Phase I/II, while bluebird has the exclusive option to take on further clinical development and commercialization worldwide.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.